Skip to main content

Table 1 Baseline characteristics of both groups (median/interquartile range)

From: Heme iron polypeptide for the treatment of iron deficiency anemia in non-dialysis chronic kidney disease patients: a randomized controlled trial

Parameter HIP IV sucrose p-value
Number of patients (Randomized) 18 22  
Age(years) 76 (66–83) 66 (58–76) 0.10
Sex Male −13 Female −5 Male −12 Female −10 0.33
Race Caucasians −16 Africans −1 Others −1 Caucasians- 15 Africans-6 Others-1 0.12
Blood pressure (mm Hg) Systolic 130 (122–140) 131 (124–140) 0.85
Blood pressure (mm Hg) Diastolic 67 (62–75) 68 (60–72) 0.76
Hemoglobin(g/L) 110.5 (104–119) 108.5 (102–117) 0.39
Serum ferritin(ug/L) 71 (40–143) 67 (27–100) 0.59
TSAT 17 (14–20) 16.5 (10–20) 0.37
Patients on ESA* 7 6 1.0
Average ESA dose (ug/month) 60(60–80) 80(60–100) 0.20
Serum creatinine(umol/L) 246.5 (206–362) 216.5 (176–351) 0.48
Glomerular filtration rate(ml/min/1.73 m2) 20.5 (12–26) 23 (18–33) 0.39
Serum albumin 38 (35–39) 38.5 (36–41) 0.58
Intact PTH 13.05 (6.1-20.1) 13.3 (7.9-16.75) 0.93
Serum phosphate 1.28 (1.07-1.42) 1.28 (1–1.54) 0.96
Cause Of ESRD Diabetes – 6 Ischemic nephropathy-3 Hypertension – 3 Unknown – 3 Others – 3 Diabetes −9 Ischemic nephropathy-6 Hypertension – 1 Unknown – 5 Others – 1 0.22